Information  X 
Enter a valid email address

Mediclinic Intnl plc (MDC)

  Print      Mail a friend

Friday 11 August, 2017

Mediclinic Intnl plc

South African B-BBEE Act: Annual Compliance Report

RNS Number : 8113N
Mediclinic International plc
11 August 2017

Mediclinic International plc
(Incorporated in England and Wales)
Company Number 8338604
LSE Share Code: MDC

JSE Share Code: MEI
NSX Share Code: MEP


LEI: 2138002S5BSBIZTD5I60

("Mediclinic" or "the Company")


11 August 2017




In accordance with the JSE Listings Requirements, applicable to the Company having a secondary listing on the JSE, notice is hereby given that the Company's annual compliance report in terms of section 13G(2) of the South African Broad-Based Black Economic Empowerment Act, 53 of 2003, as amended, (the "B-BBEE Act") was submitted to the Broad-Based Black Economic Empowerment Commission. The compliance report is available in the governance section of Mediclinic's website at


The compliance report relates to the assessment of the broad-based black economic empowerment status of Mediclinic Southern Africa (Pty) Ltd, a wholly-owned subsidiary of the Company, in respect of the Company's operations in South Africa.


About the B-BBEE Act


The B-BBEE Act was enacted to establish a legislative framework for the promotion of broad-based black economic empowerment in South Africa and is intended to encourage transformation by including black people in the economy. It covers aspects such as ownership, management control, skills development, enterprise and supplier development and social-economic development. Although compliance with the B-BBEE Act and the Codes of Good Practice issued in terms thereof is voluntary, an obligation was introduced by way of an amendment to the B-BBEE Act in 2013, which became effective in June 2016, to require public companies listed on the JSE Limited to report on their broad-based black economic empowerment status to the Broad-Based Black Economic Empowerment Commission (the "BEE Commission").


About Mediclinic International plc

Mediclinic is an international private healthcare group with operating platforms in Southern Africa (South Africa and Namibia), Switzerland and the United Arab Emirates. Its core purpose is to enhance the quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary healthcare services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a LSE listed and UK-based private healthcare group.


Mediclinic comprises 75 hospitals and 29 clinics. Mediclinic Southern Africa operates 49 hospitals and 2 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 000 inpatient beds in total; Hirslanden operates 17 private acute care facilities and 4 clinics in Switzerland with more than 1 700 inpatient beds; and Mediclinic Middle East operates 6 hospitals and 23 clinics with more than 700 inpatient beds in the United Arab Emirates.


During February 2016, the combination of the Company (previously named Al Noor Hospitals Group plc), with operations mainly in Abu Dhabi in the United Arab Emirates, and Mediclinic International Limited was completed. Mediclinic International Limited was a South African based international private healthcare group founded in 1983 and listed on the JSE, the South African stock exchange, since 1986, with operations in South Africa, Namibia, Switzerland and the United Arab Emirates (mainly in Dubai). The combination resulted in the renaming of the enlarged group to Mediclinic International plc.


Mediclinic has a primary listing on the Main Market of the LSE, with secondary listings on the JSE in South Africa and the NSX in Namibia.


For further information, please contact:


Mediclinic Southern Africa

Tertia Kruger, Corporate Communications Manager

Tel: +27 (0)21 809 6500

Email: [email protected]     


Capita Company Secretarial Services Limited

Victoria Dalby / Caroline Emmet

+44 (0)20 7954 9600


Investor Relations, Mediclinic International plc

James Arnold, Head of Investor Relations

[email protected]   

+44 (0)20 3786 8181


Media queries

FTI Consulting

Brett Pollard/Debbie Scott (UK)

+44 (0)20 3727 1000

Frank Ford (South Africa)

+27 (0)21 487 9000


Registered address: 1st Floor, 40 Dukes Place, London, EC3A 7NH, United Kingdom


Corporate broker: Morgan Stanley & Co International plc

JSE sponsor: RAND MERCHANT BANK (A division of FirstRand Bank Limited)

NSX sponsor: Simonis Storm Securities (Pty) Ltd


This information is provided by RNS
The company news service from the London Stock Exchange

a d v e r t i s e m e n t